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Human immunodeficiency virus 
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Abstract 
Background: Hepatitis B virus (HBV) genotypes have distinct geographical distributions and are associated with 
different clinical courses. HBV genotype G (HBV/G) is extremely rare among Human immunodeficiency virus (HIV) 
infected populations in Japan. Genetic analysis and clinical course of recombinant forms with HBV/G infection are 
seldom reported in the literature.
Case presentation: A 36-year old homosexual man with HIV infection was referred to a general hospital for assess-
ment of chronic HBV infection. We cloned full-length HBV isolates and determined the complete genome sequences 
of 2 obtained clones, although mixture of multiple variant with different length is detected by HBV-DNA genotyping. 
The Bootscaning analysis using a full-length HBV genome revealed the clones represented as the HBV/A2 and the 
HBV/G/A2 recombinant strain. The HBV-DNA decreased from >9.1 to 2.5 log copies/mL after 24 months of antiretrovi-
ral therapy.
Conclusions: This patient was co-infected with HBV/A2 and HBV/G/A2 recombinant strain. This recombinant strain 
was not identical to HBV/G/A2 strains previously reported from Japan. Recombination with other genotypes could 
alter the clinical manifestations of chronic hepatitis B in people living with HIV.
Keywords: Hepatitis B virus, Human immunodeficiency virus, Recombinants with HBV genotype G, Antiretroviral 
therapy
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Hepatitis B virus (HBV) infection is a major public health 
issues among human immunodeficiency virus (HIV) 
-infected people. HIV-HBV co-infection can accelerate the 
progression of chronic hepatitis resulting in fibrosis and 
hepatocelullar carcinoma (Thio et al. 2002). HIV-HBV co-
infection rate is high due to the similar transmission route 
and approximately 6.3  % of the HIV-infected patients in 
Japan are coinfected with HBV (Koike et al. 2008).
HBV is classified into ten genotypes on the basis of 
8  % divergence in the entire genomic sequence. HBV 
genotypes have distinct geographical distributions and 
are associated with different clinical courses. In HIV-
HBV coinfected patients in Japan, HBV genotype A2 
(HBV/A2) is the most frequently detected, followed far 
behind by genotype C and genotype B which are common 
in the entire chronic hepatitis B population (Yanagimoto 
et al. 2012). HBV genotype G (HBV/G) was first reported 
in 2000 from France and characterized by a unique 36 
nt insertion in the core region and the possession of 
two stop codons in the precore region that prevents 
the expression of hepatitis B envelope antigen (HBeAg) 
(Stuyver et  al. 2000). HBV/G infections were found to 
occur predominantly in males (92 %) and were primarily 
associated with male homosexual sex (67  %) in Canada 
(Osiowy et al. 2008). French studies found a high preva-
lence of patients infected with HBV/G among HIV-HBV 
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co-infected patients (12 and 25 %) (Lacombe et al. 2006; 
Desire et al. 2010). In contrast, HBV/G is extremely rare 
in Japan even in HIV-infected patients (Yanagimoto et al. 
2012; Kato et  al. 2004). One of its unique characteris-
tics is frequent co-infection with the other genotypes. 
Recombinant forms between HBV/G and the other geno-
types have been observed. However, these recombinant 
forms have been detected normally as a minority spe-
cies within the HBV quasispecies population and spe-
cific prevalent strains have not been identified (Kato et al. 
2002a, b). Some epidemiological data exhibited patients 
infected with HIV-HBV/G were at increased risk of liver 
fibrosis compared to those infected with other HBV gen-
otypes (Lacombe et  al. 2006; Dao et  al. 2011) but clini-
cal data on HBV/G is limited due to the low prevalence 
throughout the world. We report here a case of chronic 
hepatitis caused by HIV-HBV/G/A2 recombinant strain 
co-infection. These epidemiological and clinical find-
ings have warranted the need for HBV genotyping in the 
management of HIV-HBV co-infected patients.
Case presentation
In 2013, a 36 year-old Japanese man was diagnosed with 
chronic hepatitis B based on the elevated levels of liver 
enzyme and the positive hepatitis B surface antigen 
(HBsAg) at a local clinic during follow-up for flu-like 
symptoms. He was referred to the hepatology division, 
in a general hospital for further assessment of chronic 
hepatitis B. The liver biopsy showed septal fibrosis and 
infiltrating lymphocyte in his liver tissue associated with 
degeneration of limiting plate, and histologic activity 
index—METAVIR score (Thio et  al. 2002) was A2-F3. 
He had been living in Japan all his life and had no fam-
ily histories of viral hepatitis. He denied intravenous drug 
use and dissolute sexual behavior in Japan, but admitted 
occasional sexual intercourse with men in Thailand since 
he was 20 years old. The screening for HIV antigen/anti-
body test was positive and HIV infection was confirmed 
by the positive Western-blot HIV antibody test. The 
Serological HBV genotyping test by enzyme immunoas-
say (EIA) in the clinical laboratory testing industry (SRL 
Inc. Japan) showed genotype D. However, his social his-
tory was not compatible with the risk of chronically HBV 
gonotype D (HBV/D) infection because HBV/D is rare 
throughout Japan except for some areas and not preva-
lent among men who have sex with men (MSM). Then, 
HBV-DNA genotyping was performed using obtained 
isolates from this patient. We cloned full-length HBV iso-
lates and determined the complete genome sequences of 
2 obtained clones as previously reported (Sugauchi et al. 
2001). Briefly, the full length of HBV genome was ampli-
fied as two overlapping fragments by using the primer set 
to yield a 3200 bp amplicon for fragment A and another 
primer set to yield a 462  bp amplicon for fragment B. 
The fragment A or B was transferred to pGEM-T easy 
vector by TA cloning. The cloned plasmids of fragment 
A or B were sequenced and analyzed by phylogenetic 
analysis using MEGA6 (Tamura et al. 2013). The Boots-
caning analysis using RDP4 software (Martin et al. 2010) 
revealed the clones represented as the HBV/A2 and the 
HBV/G/A2 recombinant strain (Fig.  1a, b). These find-
ings indicated co-infection of HBV/A2 and HBV/G/A2. 
36 nt insertion in the core region and two stop codons in 
the precore region were not detected in the recombinant 
strain because two estimated recombination junction 
of HBV/G were from approximately nt.192 to nt.1795 
(Fig.  1b). The HBV/A2 and the HBV/G/A2 recombi-
nant strain were compared with other registered strains 
including G/A recombinants by MEGA6. Figure 2 shows 
the phylogenetic tree of these strains. Our HBV/G/A2 
were located near the clusters of HBV/G and G/A recom-
binants. Our HBV/A2 belonged to the HBV/A2 cluster. 
The HIV-RNA and CD4 T cell count were 4300 cop-
ies/mL and 226 cells/μL, respectively. The HIV subtype 
was CRF-01 AE and no primary mutations associated 
with drug resistance mutations were detected. Labora-
tory findings were as follows: platelet count, 10.6 × 104/
dL; asparate aminotransferase, 84  IU/L; alanine ami-
notransferase, 122 IU/L; alkaline phosphatase, 272 IU/L; 
γ-glutamyltranspeptidase, 34  IU/L; hepatitis B surface 
antigen (HBsAg), 93,297 IU/mL; antibodies to the HBsAg 
(anti-HBsAg), negative; total hepatitis B core antibodies, 
11.9 S/CO; HBeAg, 42.9 S/CO; antibodies to the HBeAg 
(anti-HBeAg), negative; HBV-DNA, >9.1 log copies/mL; 
hyaluronic acid, 124 ng/mL; Type IV Collagen 7 s, 7.3 ng/
mL. HBV drug resistance mutations related to lamivu-
dine, adefovir, entecavir or tenofovir were not detected. 
He received antiretroviral therapy (ART) consisting of 
tenofovir/emtricitabine (TDF/FTC) and raltegravir to 
treat HIV-HBV/G/A2 recombinant infection. Three 
months after the initiation of ART, while the HBV-DNA 
decreased steadily, the levels of liver enzyme increased 
progressively with the rapid decline of HBeAg and 
HBsAg. The CD4 T-cell count increased to 487 cells/μL. 
This presentation was consistent with HIV-HBV immune 
reconstitution inflammatory syndrome (IRIS). The levels 
of liver enzymes improved without specific treatments. 
The HBV-DNA decreased to 2.5 log copies/mL after 
24 months of ART.
Discussion
HIV infection accelerates chronic hepatitis B related liver 
diseases, and precise assessment of HBV infection is 
imperative in the management of HIV-HBV co-infected 
patients. Different HBV genotypes induce different clini-
cal features in HBV-infected patients. Recently, acute 
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b
Fig. 1 Bootscaning analysis with the following parameters: a window size of 200 bp, a step size of 20 bp, 1000 bootstrap replicates, gapstrip on 
and neighbor-joining analysis by RDP4. a HBV genotype A2 b HBV genotype G and A2 recombinant. The black arrows indicate the break points of 
genomic recombination
































































































































Fig. 2 Phylogenetic analysis. The red arrows indicate the sequences in this case: clone 1 A2, HBV/A2 (Fig. 1a). clone 2 G/A2, HBV/G/A2 recombinant 
(Fig. 1b)
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HBV infection in metropolitan areas of Japan has been 
increasingly attributed to the HBV/A2, that is trans-
mitted through sexual contacts (Tamada et  al. 2012). 
Another study in Japan found HBV/A2 is the most fre-
quent in HIV infected patients and is detected almost 
exclusively in homosexual patients (Yanagimoto et  al. 
2012). Several HBV/G/A2 recombinant strains have been 
reported among MSM patients in Japan (Tsuzuki et  al. 
2015; Kojima et  al. 2015) and all of these strains have a 
36-nt insertion of the core gene. However, the insertion 
was not detected in the HBV/G/A2 recombinant from 
our patient, suggesting a possibility that he was infected 
with the strain outside Japan. The co-infection with 
HBV/A2 and HBV/G/A2 recombinant was a rare case in 
HIV-infected patients. The HIV subtype of this patient 
is CRF_01 AE, which is a prevalent strain in South East 
Asia (Hemelaar et al. 2006). Hence, we speculated he had 
been infected with HIV-HBV in Thailand. However, epi-
demiological data regarding the prevalence of HBV/G 
or recombinant forms among HIV-infected patients are 
scarce in Asia (Araujo 2015).
There was a discrepancy between results of the HBV-
DNA genotyping and the serological genotyping test by 
EIA in this case. The reason was unclear, but recombina-
tion in the preS2-region might affect the results of the sero-
logical test by EIA that used monoclonal antibodies of a 
combination of epitopes on preS2-region products. HBV/G 
may be overlooked if a tool designed to detect recombinant 
forms with other genotypes is not used. It is assumed that 
detection technique could affect the epidemiologic study of 
HBV genotype. Full-genome sequence was occasionally dif-
ficult to be determined because of the presence of mixture 
of multiple variant with different length.
Two studies suggest that HBV/G may accelerate liver 
fibrosis progression and associated with HBeAg positiv-
ity and high HBV-DNA levels (Lacombe et al. 2006; Dao 
et al. 2011). The clinical findings in this case showed the 
advanced liver fibrosis. Recombination with HIV-HBV/
A2 co-infection, which was frequently associated with 
high HBV-DNA levels, would explain his extremely high 
HBV-DNA level. Some studies revealed co-infection with 
HBV/A2 enhanced HBV/G replication (Dao et  al. 2011; 
Kato et  al. 2002a, b; Tanaka et  al. 2008) and a in  vivo 
study demonstrated the introduction of the HBV/A2 core 
promoter or core protein or both genomic regions into 
the HBV/G genome increased HBV/G replication effi-
ciently (Tsuzuki et al. 2015; Sakamoto et al. 2013). Mean-
while, his CD4+ cell count was maintained at 226/μL, 
nevertheless HIV-HBV-IRIS occurred after the initiation 
of ART and HBV-specific CD8+ cell responses could 
be impaired. Thereafter, the impaired cellular immu-
nity caused by HIV infection may affect the progress of 
liver fibrosis. In contrast, a recent study reports HBV/G 
does not have a harmful effect on fibrosis progression 
in efficiently treated HIV–HBV co-infected patients 
(Calin et al. 2013). Prognosis of chronic hepatitis caused 
by HBV/G or recombinant forms remain controver-
sial. Long-term precise observation of clinical course is 
needed to evaluate the prognosis of this patient.
Clinical data regarding treatment for HBV/G is lim-
ited. As a rule, HIV-HBV co-infected patients regard-
less of HBV genotype receive TDF/FTC-containing ART. 
A study reported three of six patients who experienced 
HBV-DNA rebound with correct TDF serum concentra-
tion were infected with HIV-HBV/G or HIV-HBV/G/A2 
mixture (Karine Lacombe et  al. 2009). Another French 
report showed 15  % (7/45) of HIV-HBV co-infected 
patients who added TDF to lamivudine therapy expe-
rienced delayed decrease in plasma HBV-DNA levels, 
of whom four of them were infected with HBV/G (Lada 
et al. 2012). A recent report from Japan showed HBV/G/
A2 recombinant did not always cause rapid progres-
sion of disease (Kojima et al. 2015). In this present case 
detectable HBV-DNA levels have lasted for 2 years after 
the initiation of antiviral therapy. Clinical and virological 
factors to affect TDF/FTC response to HBV/G remained 
to be determined. Additionally, a case of occult infection 
with HBV/G/A2 recombinant following acute hepatitis 
B caused by HBV/A2 is reported (de Barros et al. 2015). 
Co-infection with HBV/G/A2 recombinant could be a 
risk of chronic infection caused by HBV/A2 and persis-
tent viremia.
Conclusions
This patient was infected with HBV/A2 and HBV/G/A2 
recombinant which is extremely rare in Japan. Although 
these HBV strains had no mutations related to anti-HBV 
drugs, detectable HBV-DNA levels have lasted for 2 years 
under TDF/FTC-containing ART. Clinicians should keep 
the HBV genotyping in mind using tools designed to 
detect recombinant forms in the management of HIV-
HBV co-infected patients.
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